Waltham, MA-based Augmenix, the maker of implantable material to minimize the side effects of radiation therapy, said today it has closed a Series B round of financing worth $6.1 million. Ascension Health Ventures led the round, and was joined by Versant Ventures, Pinnacle Ventures, Catalyst Health Ventures, and several private investors, the company said. The company plans to use the money for clinical and commercial development of its SpaceOAR System in the U.S. and Europe, and to develop other products in its pipeline.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
